Polymorphic transformation of indomethacin under high pressures

Journal of Pharmaceutical Sciences

Volumn 95, Issue 3, 2006, Pages 689-700

  Okumura, Takehiro ^a   Ishida, Masaya ^b   Takayama, Kozo ^c   Otsuka, Makoto ^d  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b SUMITOMO CHEMICAL CO LTD   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d MUSASHINO UNIVERSITY   (Japan)

Author keywords

Amorphous; Crystallinity; Crystallization; Indomethacin; Polymorph; Pressure; X ray powder diffractometry

Indexed keywords

ALCOHOL; INDOMETACIN;

ARTICLE; ATMOSPHERIC PRESSURE; CRYSTAL; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HYPERBARISM; POWDER; SOLID; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

EID: 33645351686     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20557     Document Type: Review

References (51)

1. Haleblian JK, McCrone W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 58:911-929.
2. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. 2001. Ritonavir: An extraordinary example of conformational polymorphism. Pharm Res 18:859-866.
3. Arai Y, Sako T, Takebayashi Y. editors. 2002. Supercritical fluids: Molecular interactions, physical properties and new applications. Berlin: Springer-Verlag.
4. Shekunov BY, York P. 2000. Crystallization process in pharmaceutical technology and drug delivery design. J Cryst Growth 211:122-136.
5. Boldyreva EV. 2003. High-pressure studies of the anisotropy of structural distortion of molecular crystals. J Mol Struct 647:159-179.
6. Takano KJ, Wakatsuki M. 1997. Development of an optical liquid high pressure cell and its application to visual observation of pressure-driven crystal growth. J Cryst Growth 171:591-600.
7. Nishiguchi N, Moritoki M, Tanabe H. 1990. In-situ observation of crystal growth of p-xylene from p-, m-mixtures by application of very high pressure. J Cryst Growth 99:1142-1146.
8. Moritoki M. 1991. High-pressure crystallization and growth behavior of organic compounds under pressure. KOBELCO Technol Rev 12:33-39.
9. Narahara H, Yamada K, Toyokura K, Moritoki M, Nishiguchi N. 1990. Observation of high-pressure crystallization of benzene from benzene-cyclohexane mixture. ACS Symposium Series 438 (Cryst. Sep. Process):281-290.
10. Moritoki M, Kitagawa K, Onoe K, Kaneko K. 1984. A pilot study of p-cresol crystallization by adiabatic application of high pressure. Process Technol Proceedings 2(Ind. Cryst.):377-380.
11. Visuri K, Kaipainen E, Kivimaki J, Niemi H, Leisola M, Palosaari S. 1990. A new method for protein crystallization using high pressure. Biotechnology 8:547-549.
12. Groß M, Jaenicke R. 1991. Growth inhibition of lysozyme crystals at high hydrostatic pressure. FEBS Lett 284:87-90.
13. Sazaki G, Nagatoshi Y, Suzuki Y, Durbin SD, Miyashita S, Nakada T, Komatsu H. 1999. Solubility of tetragonal and orthorhombic lysozyme crystals under high pressure. J Cryst Growth 196:204-209.
14. Takano KJ, Harigae K, Wakatsuki M. 1994. Corner rounding of crystals growing at high pressure. Jpn J Appl Phys 33:L663-L666.
15. Maruyama M, Kishimoto Y, Sawada T. 1997. Optical study of roughening transition on ice Ih (100) planes under pressure. J Cryst Growth 172:521-527.
16. Groß M, Jaenicke R. 1993. A kinetic model explaining the effects of hydrostatic pressure on nucleation and growth of lysozyme crystals. Biophys Chem 45:245-252.
17. Schall CA, Wieneck JM, Yarmush M, Arnold E. 1994. Lysozyme crystal growth reduced at high pressure. J Cryst Growth 135:548-554.
18. Suzuki Y, Miyashita S, Komatsu H, Sato K, Yagi T. 1994. Crystal growth of hen egg white lysozyme under high pressure. Jpn J Appl Phys 33:L1568-L1570.
19. Saikumar MV, Glatz CE, Larson MA. 1995. Crystallization of lysozyme at high pressures. J Cryst Growth 151:173-179.
20. Takano KJ, Harigae H, Kawamura Y, Ataka M. 1997. Effect of hydrostatic pressure on the crystallization of lysozyme based on in situ observations. J Cryst Growth 171:554-558.
21. Nishioka K, Mori A, Takano KJ, Kaishita Y, Narimatsu S. 1999. Pressure-dependence of the interfacial tension of a critical nucleus in the binary-ideal solution. J Cryst Growth 200:592-598.
22. Nishiguchi N, Imanishi N, Tanabe H, Moritoki M. 1991. In-situ observation of nucleation and crystal growth of p-xylene from p- and m- mixtures under very high pressure. KOBELCO Technol Rev 10:58-62.
23. Nagaoka K, Makita T, Nishiguchi N, Moritoki M. 1989. Effect of pressure on the solid-liquid phase equilibria of binary organic systems. Int J Thermophys 10:27-34.
24. Pushin NA, Grenbenshchikov JV. 1925. The influence of pressure on the equilibrium of binary systems I. Z Physik Chem 118:276-294.
25. Moritoki M, Fujikawa T. 1984. Liquid-solid phase diagram of p- and m-cresol mixtures under pressure. Process Technol Proceedings 2 (Ind. Cryst.):369-372.
26. Bridgman PW. 1915. Polymorphic transformations of solids under pressure. Proc Am Acad Arts Sci 51:55-124.
27. Maeda Y. 1999. Phase behavior of the discotic mesogen 5,10,15,20-tetrakis (4-n-dodecylphenyl) porphyrin under pressure. Liq Cryst 26:1067-1078.
28. Ibrahim HG, Pisano F, Bruno A. 1977. Polymorphism of phenylbutazone: Properties and compressional behavior of crystals. J Pharm Sci 66:669-673.
29. Matsumoto T, Kaneniwa N, Higuchi S, Otsuka M. 1991. Effects of temperature and pressure during compression on polymorphic transformation and crushing strength of chlorpropamide tablets. J Pharm Pharmacol 43:74-78.
30. Otsuka M, Matsuda Y. 1993. Effects of environmental temperature and compression energy on polymorphic transformation during tabletting. Drug Dev Ind Pharm 19:2241-2269.
31. Kaneniwa N, Otsuka M, Hayashi T. 1985. Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. Chem Pharm Bull 33:3447-3455.
32. Tada T, Kitamura S. 2000. Crystallization of medicine. In: Hirayama N, editor. Handbook of organic crystals. Tokyo: Maruzen Co. pp 109-115.
33. Ostwald W. 1987. Studien über die Bildung und Umwandlung fester Körper. Z Phys Chem 22:289-330.
34. Otsuka M, Kaneniwa N. 1988. A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem Pharm Bull 36:4026-4032.
35. Okumura T, Otsuka M. 2005. A novel standard sample powder preparation method for quantitative analysis of polymorphs. J Pharm Sci 94:1013-1023.
36. Ruland W. 1961. X-ray determination of crystal-unity and diffuse disorder scattering. Acta Cryst 14:1180-1185.
37. Chen X, Morris KR, Griesser UJ, Byrn SR, Stowell JG. 2002. Reactivity differences of indomethacin solid forms with ammonia gas. J Am Chem Soc 124:15012-15019.
38. Kistenmacher TJ, Marsh RE. 1972. Crystal and molecular structure of an antiinflammatory agent, indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2- methylindole-3-acetic acid. J Am Chem Soc 94:1340-1345.
39. Sun H. 1998. COMPASS: An ab initio forcefield optimized for condensed-phase applications-overview with details on alkane and benzene compounds. J Phys Chem B 102:7338-7364.
40. Otsuka M, Kato F, Matsuda Y. 2001. Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry. Analyst 126:1578-1582.
41. Otsuka M, Kato F, Matsuda Y. 2000. Comparative evaluation of the degree of indomethacin crystal-unity by chemoinfometrical fourier-transformed near-infrared spectroscopy and conventional powder X-ray diffractometry. AAPS Pharmsci 2(1) article 9 (http://www.pharmsci.org/)
42. Sako T, Sugeta T, Otake K, Sato M, Tsugumi M, Hiaki T, Hongo M. 1997. Decomposition of dioxins in fly ash with supercritical water oxidation. J Chem Engineer Japan 30:744-747.
43. Yoshioka M, Hancock BC, Zografi G. 1994. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83:1700-1705.
44. Galdecki Z, Glowka ML. 1976. Crystal and molecular structure of the γ-form of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid. A comparison of results based on photographic data with previous results obtained by means of a single crystal diffractometer. Rocz Chem 50:1139-1148.
45. Katrusiak A. 1991. High-pressure X-ray diffraction studies on organic crystals. Cryst Res Technol 26:523-531.
46. Boldyreva EV, Shakhtshneider TP, Vasilchenko MA, Ahsbahs H, Uchtmann H. 2000. Anisotropic crystal structure distortion of the monoclinic polymorph of acetaminophen at high hydrostatic pressures. Acta Cryst B56:299-309.
47. Borka L. 1974. The polymorphism of indomethacine: New modifications, their melting behavior and solubility. Acta Pharm Suecica 11:295-303.
48. Threlfall T. 2003. Structural and thermodynamic explanations of Ostwald's rule. Org Process Res Dev 7:1017-1027.
49. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
50. Imaizumi H, Nambu N, Nagai T. 1980. Stability and several physical properties of amorphous and crystalline forms of indomethacin. Chem Pharm Bull 28:2565-2569.
51. Fukuoka E, Makita M, Yamamura S. 1986. Some physicochemical properties of grassy indomethacin. Chem Pharm Bull 34:4314-4321.